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A cancer immune signature implicating good prognosis
and responsiveness to immunotherapy was described that
is observed also in other aspects of immune-mediated, tis-
sue-specific destruction (TSD). Its determinism remains,
however, elusive. On one side it appears that the genetic
background of the host’s bears significantly on immune
responsiveness, on the other it appears that tumor can
behave differently within the same genetic background (as
in the case of mixed responses). This apparent paradox
can only be explained by a multi-factorial model of cancer
immune responsiveness. It should be emphasized that
host and cancer genetics are largely overlapping since can-
cer cells carry the majority of the host’s genetics. Thus,
inherited genetic factors may affect the biology of cancer
cells besides that of normal cells. It could be postulated
that some patients carry a genetic background that make
them resistant to immunotherapy by effecting either the
biology of the immune response, the biology of the cancer
cells or both. On the other hand, “an immune-responsive
genotype” may still be limited by the genetics of the
tumors: in other words, although the patient may be pre-
disposed to cancer rejection the tumor lacks additional
properties necessary for its recognition by the immune
response. In this model, a favorable genetic background of
the host is necessary but not sufficient for tumor rejection
as the possession of a shotgun is necessary to shoot a duck
but at the same time a skill in shooting is required. A good
example is provided by the analysis of patients with IRF-5
polymorphism; the “immune resistant phenotype” appears
to almost exclusively preclude cancer rejection during
adoptive therapy with tumor infiltrating lymphocytes;
however, “the immune responsive phenotype” can be seg-
regated into two categories; one enriched in patients
responding to therapy and the other of non-responding.
Although, other host’s genetic factors could be responsible
for this sub-classification, it is also possible that, given a
favorable genetic background, the genetics of the tumor
may become the determining factor.
We recognize that this classification of factors that may
influence immune responsiveness may be too rigid. In rea-
lity, immune responsiveness may depend upon a conti-
nuum determined by the interaction of a multitude of
factors that for simplicity can be separated into broad
categories depending upon the host’s genetic background,
somatic mutations, and external factors such as intensity
and effectiveness of treatment, general condition of the
patient and a multitude of other hidden co-factors. In the
presentation at the NY Academy of Sciences we will pre-
sent our strategy to dissect the question of cancer immune
responsiveness by study dynamically the behavior of
human cancers under natural conditions on in response to
therapy.
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